Opendata, web and dolomites

POLYBOOST

POLYBOOST: Renovating the Polyclonal Immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 POLYBOOST project word cloud

Explore the words cloud of the POLYBOOST project. It provides you a very rough idea of what is the project "POLYBOOST" about.

full    successful    revolutionize    immunotherapy    clinicians    incidence    population    surgery    days    effect    list    organs    suppress    life    organ    efficiency    benefits    disrupt    proven    polyboost    doses    352    customized    significantly    retain    plan    europeans    time    antigenicity    cancer    influencing    immunological    prevent    achievement    registering    rejection    stimulate    stimuli    death    41    platform    immune    believe    survival    risk    customizing    medicine    waiting    safe    people    views    move    avantea    innovative    diseases    perspectives    revenues    transplanted    chronic    reducing    rising    market    autoimmune    created    patients    ageing    progressive    huge    immunosuppressants    medical    fight    xenothera    scarce    turn    financial    demand    society    commercial    transplantation    driving    safer    administered    damaged    polyclonals    severe    induce    polyclonal    waited    entering    hiring    severely   

Project "POLYBOOST" data sheet

The following table provides information about the project.

Coordinator
XENOTHERA 

Organization address
address: FACUKTE DE MEDECINE, 1 RUE GASTON VEIL
city: NANTES
postcode: 44035
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.xenothera.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    XENOTHERA FR (NANTES) coordinator 50˙000.00
2    AVANTEA srl IT (Cremona) participant 0.00

Map

 Project objective

Immunotherapy is an essential field of medicine that allows clinicians to stimulate or to suppress the response of our immune system against specific stimuli. The progressive ageing of the population and the rising incidence of chronic diseases is driving the demand for immunotherapy, as it can be used to fight cancer or autoimmune diseases. One of its major applications today is to prevent the rejection of transplanted organs. Since organs are scarce (40,000 Europeans on waiting list), patients are administered high doses of polyclonal immunosuppressants for several days around the time of surgery to prevent rejection. However, current polyclonals are not safe or reliable. Patients respond to these products by developing severe side effects that increase the risk for death & the medical costs. Thus, current polyclonals are only open for one time use. Also, the transplanted organ is severely damaged in the process, reducing its life-survival. In response, the consortium XENOTHERA & AVANTEA has created this project with the main objective of bringing to market a unique platform for the production of safer polyclonals (POLYBOOST). Our innovative method will revolutionize the field of immunotherapy, since it enables production of customized polyclonal products of low antigenicity, which retain a full immunological effect but do not induce side effects. We have proven the efficiency of POLYBOOST by customizing a polyclonal for transplantation medicine. In views of this successful achievement, we now aim to move forward towards the market. Thus, in Phase 1 we plan to assess all the aspects influencing the project from the technical, commercial and financial perspectives. We believe POLYBOOST will bring huge benefits for society and medicine, entering the market with a so long waited for product that will disrupt transplantation medicine. In turn, we expect the project to impact our growth significantly, registering €352 M in revenues and hiring 41 new people in 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "POLYBOOST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "POLYBOOST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More